FORM 3

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

## OMB APPROVAL OMB Number: 32350104 Estimated average burden hours per response: 0.5

## INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and A	Address of Rep illiam	Requiring S (Month/Day	2. Date of Event Requiring Statement (Month/Day/Year) 08/16/2021  3. Issuer Name and Ticker or Trading Symbol CORCEPT THERAPEUTICS INC [ CORT ]							
(Last) (First) (Middle) C/O CORCEPT THERAPEUTICS INCORPORATED					Relationship of Reporting Person(s) to Issuer (Check all applicable)     Director 10% Owner			5. If Amendment, Date of Original Filed (Month/Day/Year)		
149 COMM	MONWEALT			X Officer (give Other (specify below)			6. Individual or Joint/Group Filing (Check Applicable Line)  Form filed by One Reporting			
(Street) MENLO PARK	CA	94025				Chief Developme	ent Offic	er	A Person	by More than One
(City)	(State)	(Zip)								
		Та	ble I - Non	-Derivati	ve Se	curities Benefic	cially O	wned		
				Į.		Amount of Securities eneficially Owned (Instr. ) 3. Owners Form: Dire (D) or Indii (I) (Instr. 5)			4. Nature of Indirect Beneficial Ownership (Instr. 5)	
1. Title of Sec	curity (Instr. 4)						Form: [ (D) or Ir	Direct (		
1. Title of Sec	curity (Instr. 4)			erivative	Benefic 4) Secu		Form: E (D) or II (I) (Insti	Direct of the condition		
	curity (Instr. 4)	(e.g.		erivative s, warrar	Secunts, or	rities Beneficia ptions, converti le and Amount of S rlying Derivative Se	Form: E (D) or Ir (I) (Instr ally Own ible sec ecurities	Direct of the condition	5. ion Ownership	

**Explanation of Responses:** 

Remarks:

No securities are beneficially owned.

/s/ Joseph Douglas Lyon,

Attorney-in-Fact for William Guyer

08/19/2021

\*\* Signature of Reporting

Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- $^{\star}$  If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

## POWER OF ATTORNEY

KNOW ALL BY THESE PRESENTS, that the undersigned hereby constitutes and appoints Joseph K. Belanoff, M.D., in his capacity as Chief Executive Officer of Corcept Therapeutics Incorporated (the "Company"), G. Charles Robb, in his capacity as Chief Business Officer of the Company, Atabak Mokari, in his capacity as Chief Financial Officer of the Company, Joseph Douglas Lyon, in his capacity as Chief Accounting Officer of the Company, and any of them with full power of substitution of their respective successors in any such offices, as the undersigned's true and lawful attorney-in-fact to:

- (1) prepare, execute in the undersigned's name and on the undersigned's behalf, and submit to the U.S. Securities and Exchange Commission (the "SEC") a Form ID, including amendments thereto, and any other documents necessary or appropriate to obtain codes and passwords enabling the undersigned to make electronic filings with the SEC of reports required by Section 16(a) of the Securities Exchange Act of 1934 or any rule or regulation of the SEC;
- (2) execute for and on behalf of the undersigned, in the undersigned's capacity as an executive officer of the Company, Forms 3, 4, and 5 and any amendments thereto in accordance with Section 16(a) of the Securities Exchange Act of 1934 and the rules thereunder;
- (3) do and perform any and all acts for and on behalf of the undersigned which may be necessary or desirable to complete and execute any such Form 3, 4, or 5, complete and execute any amendment or amendments thereto, and timely file such form with the SEC and any stock exchange or similar authority; and
- (4) take any other action of any type whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact, may be of benefit to, in the best interest of, or legally required by, the undersigned, it being understood that the documents executed by such attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in such attorney-in-fact's discretion.

The undersigned hereby grants to such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary, or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or such attorney-in-fact's substitute or substitutes, shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted. The undersigned acknowledges that the foregoing attorneys-in-fact, in serving in such capacity at the request of the undersigned, are not assuming, nor is the Company assuming, any of the undersigned's responsibilities to comply with Section 16 of the Securities Exchange Act of 1934.

This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Forms 3, 4, and 5 with respect to the undersigned's holdings of and transactions in securities issued by the Company, unless earlier revoked by the undersigned in a signed writing delivered to the foregoing attorneys-in-fact.

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this 16th day of August, 2021.

Signature: /s/ William Guyer
William Guyer